Proteinuria in the prognosis of IgA nephropathy

Minerva Urologica e Nefrologica

Volumn 61, Issue 3, 2009, Pages 235-248

  Aucella, F ^a   Netti, G S ^b   Piemontese, M ^a   Cincione, I R ^b   Infante, B ^b   Gesualdo, L ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Angiotensin converting enzyme inhibitors; Glomerulonephritis, IGA; Kidney failure; Kidney failure, chronic; Proteinuria; Receptors, angiotensin; Risk factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE DURATION; HEREDITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; OBESITY; PROGNOSIS; PROTEINURIA; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

GLOMERULONEPHRITIS, IGA; HUMANS; PROGNOSIS; PROTEINURIA;

EID: 74849087007     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003;290:3101-14.
2. Yamagata K, Iseki K, Nitta K, Imai H, lino Y, Matsuo S et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008;12:1-8.
3. Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric patients found in mass screening. Nephron 2002;91:34-42.
4. Burton, C, Harris KP. The role of proteinuria in the progression of chronic renal failure. AmJ Kidney Dis 1996;27:765-75.
5. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384-94.
6. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998;53:1608-15.
7. Morigi M, Macconi D, Zoja C, Donadelli R1 Buelli S, Zanchi C et al. Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependentpathway. J Am Soc Nephrol 2002;13:1179-89.
8. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens 2004;13:31-7.
9. Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003;111:515-27.
10. Reich H, Tritchler D, Herzenberg AM, Kassiri Z, Zhou X, Gao W et al. Albumin activates ERK via EGF receptor in human renal epithelial cells. J Am Soc Nephrol 2005;16:1266-78.
11. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004;24:179-96.
12. Galla JH. IgA nephropathy. Kidney Int 1995;47:377-87.
13. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347:738-48.
14. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005;16:2088-97.
15. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990;89:209-15.
16. Berthoux FC, Mohey H, Afiani A. Natural history of IgA nephropathy. Semin Nephrol 2008;28:4-9.
17. Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003;63:2286-94.
18. Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. AmJ Med 2001;110:434-7.
19. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003;18:1541-8.
20. Hall CL, Bradley R, Kerr A, Attoti R, Peat D. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004;62:267-72.
21. Gutierrez E, González E, Hernández E, Morales E, Martinez MA, Usera G et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol 2007;2:51-7.
22. D'Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano DB et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. QJ Med 1986;59:363-78.
23. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. AmJ Kidney Dis 1997;29:526-32.
24. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199-207.
25. D'Amico G. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. AmJ Kidney Dis 2000;36:227-37.
26. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005;18:503-12.
27. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. AmJ Kidney Dis 1991;18:12-9.
28. Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 1994;73:79-102.
29. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001;38:728-35.
30. D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membrano-proliferative glomerulonephritis: Survey of the recent literature. Am J Kidney Dis 1992;20:315-23.
31. Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006;21:2800-8.
32. Chacko B, John GT, Neelakantan N, Korula A, Balakrishnan N, Kirubakaran MG et al. Presentation, prognosis and outcome of IgA nephropathy in Indian adults. Nephrology (Carlton) 2005;10:496-503.
33. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 1991;40:1050-4.
34. Johnston PA, Brown JS, Braumholtz DA, Davison AM. Clinico-pathological correlations and long-term follow-up in 253 United Kingdom patients with IgA nephropathy: A report from the MRC glomerulonephritis registry. Q J Med 1992;84:619-27.
35. Alamartine E, Sabatier JC, Merthoux FC. Comparison of pathological lesions on repeated renal biopsies in 73 . patients with primary IgA glomerulonephritis: Value of quantitative scoring and approach to final prognosis. Clin Nephrol 1990;34:45-51.
36. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. AmJ Kidney Dis 2002;39:493-502.
37. Nozawa R, Suzuki J, Takahashi A, Isome M, Kawasaki Y, Suzuki S et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol 2005;64:171-9.
38. Usui J, Yamagata K, Kai H, Outeki T, Yamamoto S, Muro K et al. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med 2001;40:697-702.
39. Nishi S. The prognosis of IgA nephropathy favorable or poor? Intern Med 2001;40:679-80.
40. Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese: Clinical and pathological perspectives. Nephrol Dial Transplant 2002;17:64-9.
41. Rauta V, Finne P, Fagerudd J, Rosenlöf K, Törnroth T, Grönhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function: A model for estimating risk of progression in mild disease. Clin Nephrol 2002;58:85-94.
42. Lee HS, Lee MS, Lee SM, Lee SY, Lee ES, Lee EY et al. Histological grading of IgA nephropathy predicting renal outcome: Revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant 2005;20:342-8.
43. Reich HN, Troyanov S, ScholeyJW, Cattran DC; Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18:3177-83.
44. DonadioJV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002;17:1197-203.
45. D'Amico G, Ragni A, Gandini E, Fellin G. Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 1993;104:6-13.
46. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE etal; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-52.
47. Ranieri E, Gesualdo L, Petrarulo F, Schena FP. Urinary IL6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int 1996;50:1990-2001.
48. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000;15:34-42.
49. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezène F et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. AmJ Kidney Dis 2001;37:720-7.
50. Beerman I, Novak J, Wyatt RJ, Julian BA, Gharavi AG. The genetics of IgA nephropathy. Nat Clin Pract Nephrol 2007;3:325-38.
51. Schena FP, Cerullo G, Rossini M, Lanzilotta SG, D'Altri C, Manno C. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol 2002;13:453-60.
52. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S et al. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis 2006;47:761-9.
53. Kobayashi Y, Tateno S, Hiki Y, Shigematsu H. IgA nephropathy: Prognostic significance of proteinuria and histological alterations. Nephron 1983;34:146-53.
54. Feehally J. Predicting prognosis in IgA nephropathy: editorial. AmJ Kidney Dis 2001;38:881-3.
55. Kobayashi Y, Kokubo T, Horii A. Prognostic prediction of long-term clinical courses in individual IgA nephropathy patients. Nephrology 1997;3:35-40.
56. Eiro M, Katoh T, Kuriki M, Asano K, Watanabe K, Watanabe T. The product of duration and amount of proteinuria (proteinuria index) is a possible marker for glomerular and tubulointerstitial damage in IgA nephropathy. Nephron 2002;90:432-41.
57. Frimat L, Briancon S, Hestin D, Aymard B, Renoult E, Huu TC et al. IgA nephropathy: Prognostic classification of end-stage renal failure. L'Association des Nephrologues de l'Est. Nephrol Dial Transplant 1997;12:2569-75.
58. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 2005;16:1061-8.
59. Nagy J, Miltényi M, Dobos M, Burger T. Tubular proteinuria in IgA glomerulonephritis. Clin Nephrol 1987;27:76-8.
60. Woo KT, Lau YK, Lee GS, Wei SS, Lim CH. Pattern of proteinuria in IgA nephritis by SDS-PAGE: clinical significance. Clin Nephrol 1991;36:6-11.
61. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003;63:809-25.
62. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002;61:1475-85.
63. Rocchetti MT, Centra M, Papale M, Bortone G, Palermo C, Centonze D et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008;8:206-16.
64. De Zeeuw D. Targeting proteinuria as a valid surrogate for individualized kidney protective therapy. Am J Kidney Dis 2008;51:713-6.
65. Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000;54:360-5.
66. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size selectivity in IgA nephropathy. Kidney Int 1991;39:1267-73.
67. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994;9:265-9•
68. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994;23:247-54.
69. Kanno Y, Okada H, Yamaji Y, Nakazato Y, Suzuki H. Angiotensin-converting- enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. QJM 2005;98:199-203.
70. Praga M, Gutierrez E, Gonzalez E, Morales E. Treatment of IgA nephropathy with ACE Inhibitors: A randomized and controlled trial. J Am Soc Nephrol 2003;14:1578-83.
71. Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK et al Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. AmJ Kidney Dis 2006;47:751-60.
72. de Zeeuw D, Remuzzi G, Parving HH. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: essons from RENAAL. Kidney Int 2004;65:2309-20.
73. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165:947-53.
74. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-7.
75. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540-6.
76. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R et al. IgACE. A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria. J Am Soc Nephrol 2007;18:1880-8.
77. Cattran DC. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy? J Am Soc Nephrol 2007;18:1633-4.
78. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Délies C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005;16:3038-45.
79. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68(3): 1190-98.
80. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-6.
81. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. AmJ Kidney Dis 2001;38:18-25.
82. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.
83. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008;52:475-85.
84. Jacobsen PK. Preventing end-stage renal disease in diabetic patients dual blockade of the renin-angiotensin system (Part II). J Renin Angiotensin Aldosterone Syst 2005;6:55-68.
85. Nakao N, Yoshimura A, Monta H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003;361:117-24.
86. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-85.
87. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-9.
88. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008;19:999-1007.
89. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995;10:497-504.
90. Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998;9:2308-17.
91. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlovâ M, OlsovskyJ et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13:1615-25.
92. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68:2823-8.
93. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK. Oral Calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 2008;51:724-31.
94. Audhya P. A Study of paricalcitol capsules on reducing albuminuria in type 2 diabetic nephropathy being treated with renin-angiotensin system inhibitors (ClinicalTrials.gov Identifier: NCT0O421733). [Last updated: 2008 November 14; cited 2009 July 27]. Available at http://clinicaltrials.gov/ct2/ show/NCT00421733.
95. Bos H, Andersen S, Rossing P, De Zeeuw D, Parving HH, De Jong PE et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 2000; (Suppl.75):S32-7.